Important Update: Buprenorphine Base 0.5mg/ml, 1.0 mg/mL, 3.0 mg/mL-Currently unavailable from Wedgewood Pharmacy

An email was sent out on June 4th, 2024 to all Washington State University users of extended-release buprenorphine compounded from Wedgewood pharmacy indicating that all formulations are currently unavailable until mid-to-late July & October 2024. This includes compounded Bup ER 0.5 mg/ml, 1.0 mg/ml and 3.0 mg/ml which is not available until October. Please see […]

Categories: Uncategorized

Controlled Substances News-Buprenorphine Extended Release for Rodents

In 2020, Fidelis Pharmaceuticals made available the first FDA-indexed extended-release buprenorphine formulation (Ethiqa XR®(link is external)) specifically for mice and rats. Recent FDA guidance GFI #256 Compounding Animal Drugs from Bulk Drug Substances has been implemented that may impact the future use of Buprenorphine ER (formerly Buprenorphine SR). Campus Veterinary Services encourages labs to review their use […]

Categories: Uncategorized

OCV Implements 100 % Environmental Monitoring for Rodent Health Program

Environmental sampling in IVS and PLAR facilities will reduce the number of live sentinel animals needed and increase sensitivity and accuracy of testing, among other benefits. Learn more in this letter from Dr. Woodford, and the PowerPoint presentation “Replacing Sentinel Rodents with Environmental Health Monitoring.”

Categories: General

Urgent Notice: Standard Xylazine Concentration No Longer Available.

As of April 2023, standard concentration of xylazine (20 mg/ml-AnaSed) is no longer available. This specific formulation was manufactured by a supplier (Akorn Pharmaceuticals) that has gone out of business and as such, the product has been discontinued. Currently, there are no other suppliers manufacturing a similar xylazine injectable product with a 20 mg/ml concentration. […]

Categories: Uncategorized